Skip to main content
    C

    Cogent Biosciences Inc (COGT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $27.85
    +0.41 (+1.49%)

    Market Cap: $4.97B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Cogent Biosciences Inc (COGT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Cogent Biosciences (COGT) has a market cap of $4.97B and an enterprise value of $4.98B. Its share count is up 23.81% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 0.16% above the market cap, as debt exceeds cash.

    Market Cap$4.97B
    Enterprise Value$4.98B
    Latest price (Nov 17, 2026)$27.85

    Key Dates

    The next earnings report is expected on Feb 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 15, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.24% in the quarter ended Sep 30, 2026 and grew 25.36% a year over 2 years.

    Shares Outstanding173.13M
    Shares Change (YoY)+23.81%
    Shares Change (QoQ)+1.24%
    Share Count Growth (2Y CAGR)+25.36%

    Valuation Ratios

    Forward P/S952.5x
    P/B Ratio9.3x

    Price Statistics

    The stock is down 16.96% over 52 weeks and trades 10.45% below its 50-day average.

    Beta (1Y)1.36
    52-Week Change-16.96%
    1-Month Change-7.20%
    3-Month Change-24.42%
    6-Month Change-10.88%
    5-Year Change+265.80%
    Total Return (1Y)-16.96%
    Total Return (3Y CAGR)+51.67%
    Total Return (5Y CAGR)+22.10%
    Return vs SPY (1Y)-28.18%
    Max Drawdown (1Y)-35.95%
    Max Drawdown (3Y)-67.32%
    Sharpe Ratio (1Y)-0.40
    Correlation with SPY (1Y)0.41
    50-Day Average$31.10
    200-Day Average$35.21
    52-Week Range$27.23 to $43.73
    RSI (14 Days)39.4
    Average Volume (20 Days)2.10M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 10.99x current liabilities, and total debt is 0.44x shareholder equity.

    Current Ratio10.99x
    Quick Ratio10.99x
    Debt / Equity0.44x
    Interest Coverage-82.07x

    Returns and Efficiency

    Return on invested capital is -43.38% over the last 12 months, against a 5-year average of -50.90%.

    Return on Equity (ROE)-78.97%
    Return on Assets (ROA)-48.99%
    Return on Invested Capital (ROIC)-43.38%
    Return on Capital Employed (ROCE)-53.65%
    ROE (5Y Average)-62.35%
    ROA (5Y Average)-49.95%
    ROIC (5Y Average)-50.90%

    Scores

    COGT has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Operating Income-$422.92M
    Pretax Income-$407.68M
    Net Income-$407.68M
    EBITDA-$403.64M
    EBIT-$407.25M
    Reported EPS (TTM)-$2.20

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 62.04% of the $832.14M in total assets.

    Cash and Equivalents$217.46M
    Total Debt$225.32M
    Net Debt$7.86M
    Net Debt Per Share$0.05
    Working Capital$730.47M
    Shareholder Equity$516.26M
    Book Value Per Share$2.98
    Total Assets$832.14M
    Total Liabilities$315.88M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.74M of capital spending, operating cash flow left -$325.78M of free cash flow.

    Operating Cash Flow-$324.05M
    Capital Expenditures$1.74M
    Free Cash Flow-$325.78M
    FCF Per Share-$1.87
    Depreciation and Amortization$3.61M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+15.32%
    Tangible Book Per Share Growth (2Y CAGR)+15.32%

    Revenue and profit by year

    Dividends and Yields

    COGT does not pay a dividend. Its free cash flow yield is -6.76%.

    FCF Yield-6.76%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-4 reverse split on Nov 9, 2020.

    Last Split DateNov 9, 2020
    Split TypeReverse split
    Split Ratio1:4

    Peer Position

    Against 9 similar companies, COGT has the 9th highest ROIC.

    ROIC-43.38% vs -25.19% median
    Revenue Growth (Trailing 4 Quarters, YoY)-100.00% vs -34.34% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About COGT

    What is COGT's market cap?

    Cogent Biosciences has a market cap of $4.97B. Its enterprise value, which adds debt and subtracts cash, is $4.98B.

    How many shares of COGT are outstanding?

    Cogent Biosciences has 173.13M shares outstanding. The count is up 23.81% from a year earlier.

    Does COGT pay a dividend?

    No. Cogent Biosciences does not pay a dividend.

    How much debt does COGT have?

    Cogent Biosciences has $225.32M of total debt and $217.46M of cash and equivalents, a net debt position of $7.86M.